Artemisinin derivatives for treating severe malaria.

Area of Science:

• Tropical Medicine
• Infectious Diseases
• Pharmacology

Background:

• Artemisinin derivatives offer potential advantages for severe malaria treatment due to rapid action and efficacy against resistant strains.
• Severe malaria remains a significant global health challenge, necessitating effective therapeutic options.

Purpose of the Study:

• To systematically review and assess the efficacy and safety of artemisinin drugs for treating severe and complicated falciparum malaria in both adults and children.
• To compare artemisinin-based treatments with standard quinine therapy.

Main Methods:

• Comprehensive literature search across multiple databases (Cochrane, Medline, Embase) and other sources.
• Inclusion of randomized and pseudo-randomized trials comparing artemisinin drugs with standard treatment or other artemisinin derivatives.
• Independent data extraction and quality assessment by two reviewers, with author contact for additional information.

Main Results:

• Artemisinin drugs demonstrated a statistically significant reduction in mortality (OR 0.61) compared to quinine in severe malaria patients.
• While overall mortality was lower with artemisinin drugs in cerebral malaria cases (OR 0.63), this was not significant in trials with adequate allocation concealment.
• Artemisinin drugs facilitated faster parasite clearance with comparable adverse effect profiles to quinine; no significant difference in neurological sequelae was observed.

Conclusions:

• Current evidence suggests artemisinin drugs are at least as effective as quinine in preventing death from severe or complicated malaria.
• No specific artemisinin derivative has shown superiority over others in treating severe malaria.